Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)</title><author><name sortKey="Hodi, F Stephen" sort="Hodi, F Stephen" uniqKey="Hodi F" first="F Stephen" last="Hodi">F Stephen Hodi</name><affiliation><nlm:aff id="I1">Dana-Farber Cancer Institute, Boston, MA, USA</nlm:aff></affiliation></author><author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><affiliation><nlm:aff id="I2">University of California, Los Angeles, CA, USA</nlm:aff></affiliation></author><author><name sortKey="Daud, Adil" sort="Daud, Adil" uniqKey="Daud A" first="Adil" last="Daud">Adil Daud</name><affiliation><nlm:aff id="I3">University of California, San Francisco, CA, USA</nlm:aff></affiliation></author><author><name sortKey="Hamid, Omid" sort="Hamid, Omid" uniqKey="Hamid O" first="Omid" last="Hamid">Omid Hamid</name><affiliation><nlm:aff id="I4">The Angeles Clinic and Research Institute, Los Angeles, CA, USA</nlm:aff></affiliation></author><author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name><affiliation><nlm:aff id="I5">Gustave Roussy, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Kefford, Richard" sort="Kefford, Richard" uniqKey="Kefford R" first="Richard" last="Kefford">Richard Kefford</name><affiliation><nlm:aff id="I6">Westmead Hospital and Melanoma Institute of Australia, NSW, Australia</nlm:aff></affiliation></author><author><name sortKey="Hwu, Wen Jen" sort="Hwu, Wen Jen" uniqKey="Hwu W" first="Wen-Jen" last="Hwu">Wen-Jen Hwu</name><affiliation><nlm:aff id="I7">The University of Texas, MD Anderson Cancer Center, Houston, TX, USA</nlm:aff></affiliation></author><author><name sortKey="Gangadhar, Tara C" sort="Gangadhar, Tara C" uniqKey="Gangadhar T" first="Tara C" last="Gangadhar">Tara C. Gangadhar</name><affiliation><nlm:aff id="I8">Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Joshua, Anthony M" sort="Joshua, Anthony M" uniqKey="Joshua A" first="Anthony M" last="Joshua">Anthony M. Joshua</name><affiliation><nlm:aff id="I9">Princess Margaret Cancer Centre, Toronto, ON, Canada</nlm:aff></affiliation></author><author><name sortKey="Hersey, Peter" sort="Hersey, Peter" uniqKey="Hersey P" first="Peter" last="Hersey">Peter Hersey</name><affiliation><nlm:aff id="I10">University of Sydney, Sydney, NSW, Australia</nlm:aff></affiliation></author><author><name sortKey="Weber, Jeffrey" sort="Weber, Jeffrey" uniqKey="Weber J" first="Jeffrey" last="Weber">Jeffrey Weber</name><affiliation><nlm:aff id="I11">H. Lee Moffitt Cancer Center, Tampa, FL, USA</nlm:aff></affiliation></author><author><name sortKey="Joseph, Richard W" sort="Joseph, Richard W" uniqKey="Joseph R" first="Richard W" last="Joseph">Richard W. Joseph</name><affiliation><nlm:aff id="I12">Mayo Clinic, Rochester, MN, USA</nlm:aff></affiliation></author><author><name sortKey="Zarour, Hassane" sort="Zarour, Hassane" uniqKey="Zarour H" first="Hassane" last="Zarour">Hassane Zarour</name><affiliation><nlm:aff id="I13">University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Dronca, Roxana" sort="Dronca, Roxana" uniqKey="Dronca R" first="Roxana" last="Dronca">Roxana Dronca</name><affiliation><nlm:aff id="I12">Mayo Clinic, Rochester, MN, USA</nlm:aff></affiliation></author><author><name sortKey="Gammage, Linda" sort="Gammage, Linda" uniqKey="Gammage L" first="Linda" last="Gammage">Linda Gammage</name><affiliation><nlm:aff id="I14">Merck & Co, USA</nlm:aff></affiliation></author><author><name sortKey="Hille, Darcy" sort="Hille, Darcy" uniqKey="Hille D" first="Darcy" last="Hille">Darcy Hille</name><affiliation><nlm:aff id="I14">Merck & Co, USA</nlm:aff></affiliation></author><author><name sortKey="Xue, Dahai" sort="Xue, Dahai" uniqKey="Xue D" first="Dahai" last="Xue">Dahai Xue</name><affiliation><nlm:aff id="I14">Merck & Co, USA</nlm:aff></affiliation></author><author><name sortKey="Kang, S Peter" sort="Kang, S Peter" uniqKey="Kang S" first="S Peter" last="Kang">S Peter Kang</name><affiliation><nlm:aff id="I14">Merck & Co, USA</nlm:aff></affiliation></author><author><name sortKey="Chun, Patrick" sort="Chun, Patrick" uniqKey="Chun P" first="Patrick" last="Chun">Patrick Chun</name><affiliation><nlm:aff id="I14">Merck & Co, USA</nlm:aff></affiliation></author><author><name sortKey="Ebbinghaus, Scot W" sort="Ebbinghaus, Scot W" uniqKey="Ebbinghaus S" first="Scot W" last="Ebbinghaus">Scot W. Ebbinghaus</name><affiliation><nlm:aff id="I14">Merck & Co, USA</nlm:aff></affiliation></author><author><name sortKey="Perrone, Andrea" sort="Perrone, Andrea" uniqKey="Perrone A" first="Andrea" last="Perrone">Andrea Perrone</name><affiliation><nlm:aff id="I14">Merck & Co, USA</nlm:aff></affiliation></author><author><name sortKey="Wolchok, Jedd D" sort="Wolchok, Jedd D" uniqKey="Wolchok J" first="Jedd D" last="Wolchok">Jedd D. Wolchok</name><affiliation><nlm:aff id="I15">Memorial Sloan Kettering Cancer Center, New York, NY, USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmc">4288385</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288385</idno><idno type="RBID">PMC:4288385</idno><idno type="doi">10.1186/2051-1426-2-S3-P103</idno><idno type="pmid">NONE</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">001161</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001161</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)</title><author><name sortKey="Hodi, F Stephen" sort="Hodi, F Stephen" uniqKey="Hodi F" first="F Stephen" last="Hodi">F Stephen Hodi</name><affiliation><nlm:aff id="I1">Dana-Farber Cancer Institute, Boston, MA, USA</nlm:aff></affiliation></author><author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><affiliation><nlm:aff id="I2">University of California, Los Angeles, CA, USA</nlm:aff></affiliation></author><author><name sortKey="Daud, Adil" sort="Daud, Adil" uniqKey="Daud A" first="Adil" last="Daud">Adil Daud</name><affiliation><nlm:aff id="I3">University of California, San Francisco, CA, USA</nlm:aff></affiliation></author><author><name sortKey="Hamid, Omid" sort="Hamid, Omid" uniqKey="Hamid O" first="Omid" last="Hamid">Omid Hamid</name><affiliation><nlm:aff id="I4">The Angeles Clinic and Research Institute, Los Angeles, CA, USA</nlm:aff></affiliation></author><author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name><affiliation><nlm:aff id="I5">Gustave Roussy, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Kefford, Richard" sort="Kefford, Richard" uniqKey="Kefford R" first="Richard" last="Kefford">Richard Kefford</name><affiliation><nlm:aff id="I6">Westmead Hospital and Melanoma Institute of Australia, NSW, Australia</nlm:aff></affiliation></author><author><name sortKey="Hwu, Wen Jen" sort="Hwu, Wen Jen" uniqKey="Hwu W" first="Wen-Jen" last="Hwu">Wen-Jen Hwu</name><affiliation><nlm:aff id="I7">The University of Texas, MD Anderson Cancer Center, Houston, TX, USA</nlm:aff></affiliation></author><author><name sortKey="Gangadhar, Tara C" sort="Gangadhar, Tara C" uniqKey="Gangadhar T" first="Tara C" last="Gangadhar">Tara C. Gangadhar</name><affiliation><nlm:aff id="I8">Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Joshua, Anthony M" sort="Joshua, Anthony M" uniqKey="Joshua A" first="Anthony M" last="Joshua">Anthony M. Joshua</name><affiliation><nlm:aff id="I9">Princess Margaret Cancer Centre, Toronto, ON, Canada</nlm:aff></affiliation></author><author><name sortKey="Hersey, Peter" sort="Hersey, Peter" uniqKey="Hersey P" first="Peter" last="Hersey">Peter Hersey</name><affiliation><nlm:aff id="I10">University of Sydney, Sydney, NSW, Australia</nlm:aff></affiliation></author><author><name sortKey="Weber, Jeffrey" sort="Weber, Jeffrey" uniqKey="Weber J" first="Jeffrey" last="Weber">Jeffrey Weber</name><affiliation><nlm:aff id="I11">H. Lee Moffitt Cancer Center, Tampa, FL, USA</nlm:aff></affiliation></author><author><name sortKey="Joseph, Richard W" sort="Joseph, Richard W" uniqKey="Joseph R" first="Richard W" last="Joseph">Richard W. Joseph</name><affiliation><nlm:aff id="I12">Mayo Clinic, Rochester, MN, USA</nlm:aff></affiliation></author><author><name sortKey="Zarour, Hassane" sort="Zarour, Hassane" uniqKey="Zarour H" first="Hassane" last="Zarour">Hassane Zarour</name><affiliation><nlm:aff id="I13">University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Dronca, Roxana" sort="Dronca, Roxana" uniqKey="Dronca R" first="Roxana" last="Dronca">Roxana Dronca</name><affiliation><nlm:aff id="I12">Mayo Clinic, Rochester, MN, USA</nlm:aff></affiliation></author><author><name sortKey="Gammage, Linda" sort="Gammage, Linda" uniqKey="Gammage L" first="Linda" last="Gammage">Linda Gammage</name><affiliation><nlm:aff id="I14">Merck & Co, USA</nlm:aff></affiliation></author><author><name sortKey="Hille, Darcy" sort="Hille, Darcy" uniqKey="Hille D" first="Darcy" last="Hille">Darcy Hille</name><affiliation><nlm:aff id="I14">Merck & Co, USA</nlm:aff></affiliation></author><author><name sortKey="Xue, Dahai" sort="Xue, Dahai" uniqKey="Xue D" first="Dahai" last="Xue">Dahai Xue</name><affiliation><nlm:aff id="I14">Merck & Co, USA</nlm:aff></affiliation></author><author><name sortKey="Kang, S Peter" sort="Kang, S Peter" uniqKey="Kang S" first="S Peter" last="Kang">S Peter Kang</name><affiliation><nlm:aff id="I14">Merck & Co, USA</nlm:aff></affiliation></author><author><name sortKey="Chun, Patrick" sort="Chun, Patrick" uniqKey="Chun P" first="Patrick" last="Chun">Patrick Chun</name><affiliation><nlm:aff id="I14">Merck & Co, USA</nlm:aff></affiliation></author><author><name sortKey="Ebbinghaus, Scot W" sort="Ebbinghaus, Scot W" uniqKey="Ebbinghaus S" first="Scot W" last="Ebbinghaus">Scot W. Ebbinghaus</name><affiliation><nlm:aff id="I14">Merck & Co, USA</nlm:aff></affiliation></author><author><name sortKey="Perrone, Andrea" sort="Perrone, Andrea" uniqKey="Perrone A" first="Andrea" last="Perrone">Andrea Perrone</name><affiliation><nlm:aff id="I14">Merck & Co, USA</nlm:aff></affiliation></author><author><name sortKey="Wolchok, Jedd D" sort="Wolchok, Jedd D" uniqKey="Wolchok J" first="Jedd D" last="Wolchok">Jedd D. Wolchok</name><affiliation><nlm:aff id="I15">Memorial Sloan Kettering Cancer Center, New York, NY, USA</nlm:aff></affiliation></author></analytic><series><title level="j">Journal for Immunotherapy of Cancer</title><idno type="eISSN">2051-1426</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Hodi, Fs" uniqKey="Hodi F">FS Hodi</name></author><author><name sortKey="Ribas, A" uniqKey="Ribas A">A Ribas</name></author><author><name sortKey="Daud, A" uniqKey="Daud A">A Daud</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="abstract" xml:lang="en"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4288385</article-id><article-id pub-id-type="publisher-id">2051-1426-2-S3-P103</article-id><article-id pub-id-type="doi">10.1186/2051-1426-2-S3-P103</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Hodi</surname><given-names>F Stephen</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Ribas</surname><given-names>Antoni</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Daud</surname><given-names>Adil</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Hamid</surname><given-names>Omid</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Robert</surname><given-names>Caroline</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Kefford</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Hwu</surname><given-names>Wen-Jen</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Gangadhar</surname><given-names>Tara C</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Joshua</surname><given-names>Anthony M</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Hersey</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Weber</surname><given-names>Jeffrey</given-names></name><xref ref-type="aff" rid="I11">11</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Joseph</surname><given-names>Richard W</given-names></name><xref ref-type="aff" rid="I12">12</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Zarour</surname><given-names>Hassane</given-names></name><xref ref-type="aff" rid="I13">13</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>Dronca</surname><given-names>Roxana</given-names></name><xref ref-type="aff" rid="I12">12</xref></contrib><contrib contrib-type="author" id="A15"><name><surname>Gammage</surname><given-names>Linda</given-names></name><xref ref-type="aff" rid="I14">14</xref></contrib><contrib contrib-type="author" id="A16"><name><surname>Hille</surname><given-names>Darcy</given-names></name><xref ref-type="aff" rid="I14">14</xref></contrib><contrib contrib-type="author" id="A17"><name><surname>Xue</surname><given-names>Dahai</given-names></name><xref ref-type="aff" rid="I14">14</xref></contrib><contrib contrib-type="author" id="A18"><name><surname>Kang</surname><given-names>S Peter</given-names></name><xref ref-type="aff" rid="I14">14</xref></contrib><contrib contrib-type="author" id="A19"><name><surname>Chun</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="I14">14</xref></contrib><contrib contrib-type="author" id="A20"><name><surname>Ebbinghaus</surname><given-names>Scot W</given-names></name><xref ref-type="aff" rid="I14">14</xref></contrib><contrib contrib-type="author" id="A21"><name><surname>Perrone</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="I14">14</xref></contrib><contrib contrib-type="author" id="A22"><name><surname>Wolchok</surname><given-names>Jedd D</given-names></name><xref ref-type="aff" rid="I15">15</xref></contrib></contrib-group><aff id="I1"><label>1</label>Dana-Farber Cancer Institute, Boston, MA, USA</aff><aff id="I2"><label>2</label>University of California, Los Angeles, CA, USA</aff><aff id="I3"><label>3</label>University of California, San Francisco, CA, USA</aff><aff id="I4"><label>4</label>The Angeles Clinic and Research Institute, Los Angeles, CA, USA</aff><aff id="I5"><label>5</label>Gustave Roussy, Villejuif, France</aff><aff id="I6"><label>6</label>Westmead Hospital and Melanoma Institute of Australia, NSW, Australia</aff><aff id="I7"><label>7</label>The University of Texas, MD Anderson Cancer Center, Houston, TX, USA</aff><aff id="I8"><label>8</label>Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA</aff><aff id="I9"><label>9</label>Princess Margaret Cancer Centre, Toronto, ON, Canada</aff><aff id="I10"><label>10</label>University of Sydney, Sydney, NSW, Australia</aff><aff id="I11"><label>11</label>H. Lee Moffitt Cancer Center, Tampa, FL, USA</aff><aff id="I12"><label>12</label>Mayo Clinic, Rochester, MN, USA</aff><aff id="I13"><label>13</label>University of Pittsburgh, Pittsburgh, PA, USA</aff><aff id="I14"><label>14</label>Merck & Co, USA</aff><aff id="I15"><label>15</label>Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>6</day><month>11</month><year>2014</year></pub-date><volume>2</volume><issue>Suppl 3</issue><supplement><named-content content-type="supplement-title">Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)</named-content></supplement><fpage>P103</fpage><lpage>P103</lpage><permissions><copyright-statement>Copyright © 2014 Hodi et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Hodi et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.immunotherapyofcancer.org/content/2/S3/P103"></self-uri><conference><conf-date>6-9 November 2014</conf-date><conf-name>Society for Immunotherapy of Cancer 29th Annual Meeting</conf-name></conference></article-meta></front><body><sec><title>Background</title><p>Unique patterns of response have been observed with immunotherapies. Notably, objective response and prolonged disease stabilization can occur after an initial increase in tumor burden. irRC were developed to better characterize response to immunotherapy based on data for Ipilimumab. We previously showed that patients with melanoma treated with the anti-PD-1 monoclonal antibody Pembrolizumab may also experience unique patterns of response and that conventional response criteria may underestimate the therapeutic benefit of Pembrolizumab [<xref ref-type="bibr" rid="B1">1</xref>]. We updated our initial analysis to include an additional 6 months of follow-up.</p></sec><sec sec-type="methods"><title>Methods</title><p>Patients from 3 melanoma cohorts treated with Pembrolizumab 2 mg/kg Q3W, 10 mg/kg Q3W, or 10 mg/kg Q2W in the Phase I KEYNOTE-001 trial served as the source population. Tumor imaging was performed every 12 weeks. Response was assessed by irRC and RECIST v1.1 by independent central review. Patients were managed by irRC by investigator. Early and delayed pseudo-progression were identified using centrally assessed irRC data among patients treated with Pembrolizumab who were followed by imaging for ≥28 weeks as of May 2014. Early pseudo-progression was defined as unconfirmed PD at assessment 1 (ie, week 12) and non-PD at assessment 2. Delayed pseudo-progression was defined as PD at any time point followed by non-PD at the next assessment. Survival data as of May 2014 were analyzed in all 411 patients enrolled in KEYNOTE-001.</p></sec><sec sec-type="results"><title>Results</title><p>Following an incremental assessment of 6 months, there were an additional 16 patients with ≥28 weeks of imaging follow-up (n = 208 total), 1 additional patient who experienced early pseudo-progression (n = 8 total; 3.8%), and 2 additional patients who experienced delayed pseudo-progression (n = 9 total; 4.3%). This corresponded to a 0.9% increase in atypical responses compared with the previous assessment. Based on analysis of best overall response in the total population (n = 411), 2 additional patients had PD by RECIST but CR/PR/SD by irRC (n = 53 total). These 53 patients had favorable OS compared with the 145 patients who had PD by both criteria (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Kaplan-Meier Estimates of OS</bold>.</p></caption><graphic xlink:href="2051-1426-2-S3-P103-1"></graphic></fig></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Pembrolizumab-treated patients with melanoma may experience unique patterns of response and should be managed accordingly. Analysis of OS suggests that conventional RECIST may underestimate the benefit of Pembrolizumab in approximately 10% of patients. These and other data suggest that new standards for response criteria should be considered for PD-1 inhibitors and other immunotherapies.</p><p>Registration <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">http://ClinicalTrials.gov</ext-link>, unique identifier NCT01295827</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Daud</surname><given-names>A</given-names></name><etal></etal><article-title>Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475</article-title><source>J Clin Oncol</source><year>2014</year><volume>32</volume><issue>suppl 5</issue><fpage>Abstr 3006</fpage></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0011618 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0011618 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |